Literature DB >> 27568161

Second Primary Lung Cancers Demonstrate Better Survival with Surgery than Radiation.

Emanuela Taioli1, Dong-Seok D Lee2, Andrew Kaufman2, Andrea Wolf2, Kenneth Rosenzweig3, Jorge Gomez4, Raja M Flores5.   

Abstract

Patients who have had curative surgery for lung cancer are at the highest risk of developing a new lung cancer. Individual studies are usually underpowered to describe the clinical characteristics and outcomes in second primary lung cancer (SPLC). The goal of this study is to determine which treatment is best associated with survival in patients who develop a new primary lung cancer. All pathologically proven stage I lung cancer cases that received cancer-directed surgery included in the Surveillance Epidemiology and End Results database between 2004 and 2010 were selected. Cases that received radiation therapy were excluded. Cases that developed a SPLC 6 or more months after the diagnosis of the first cancer were analyzed. The original data set consisted of 9564 stage I lung cancer cases treated with surgery; 520 of them developed a second primary, and completed data were available for 494 of them. Stage I disease was diagnosed in 272 patients with SPLCs (58.5%); 45.8% of these underwent cancer surgery alone, and 31.6% received radiation alone. Surgery was performed more frequently in early stages and younger patients. Surgical patients had statistically significant longer survival than patients treated with radiation (log-rank P < 0.0001) or not treated with surgery or radiation (log-rank P < 0.0001). The incidence of SPLCs was 5.4%. Stage I second primaries had improved survival when compared with later stage disease, and surgery conferred an increased survival benefit as compared with radiation.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cancer registry; cancer outcome; cancer treatment; epidemiology

Mesh:

Year:  2016        PMID: 27568161     DOI: 10.1053/j.semtcvs.2016.02.010

Source DB:  PubMed          Journal:  Semin Thorac Cardiovasc Surg        ISSN: 1043-0679


  4 in total

1.  Surface-fill hydrogel attenuates the oncogenic signature of complex anatomical surface cancer in a single application.

Authors:  Poulami Majumder; Anand Singh; Ziqiu Wang; Kingshuk Dutta; Roma Pahwa; Chen Liang; Caroline Andrews; Nimit L Patel; Junfeng Shi; Natalia de Val; Scott T R Walsh; Albert Byungyun Jeon; Baktiar Karim; Chuong D Hoang; Joel P Schneider
Journal:  Nat Nanotechnol       Date:  2021-09-23       Impact factor: 40.523

2.  Prognostic Nomogram and Therapeutic Option of Cancer-Specific Death in the Patients with Metachronous Second Primary Lung Cancer.

Authors:  Jiahui Wang; Zhen Chen; Daokui Xia; Xinyu Song; Zhigang Hu
Journal:  J Oncol       Date:  2022-01-18       Impact factor: 4.375

3.  Surgical outcomes of ipsilateral metachronous second primary lung cancer.

Authors:  Seijiro Sato; Yuki Shimizu; Tatsuya Goto; Terumoto Koike; Takahisa Koizumi; Takehiro Watanabe; Hirohiko Shinohara; Yasushi Yamato; Masanori Tsuchida
Journal:  Interact Cardiovasc Thorac Surg       Date:  2021-05-27

4.  Risk Factors Associated with a Second Primary Lung Cancer in Patients with an Initial Primary Lung Cancer.

Authors:  Amanda Fisher; Seongho Kim; Dina Farhat; Kimberly Belzer; MaryAnn Milczuk; Courtney French; Hirva Mamdani; Ammar Sukari; Frank Baciewicz; Ann G Schwartz; Antoinette Wozniak; Misako Nagasaka
Journal:  Clin Lung Cancer       Date:  2021-04-23       Impact factor: 4.785

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.